Irina Murakhovskaya, MD
Hematology & Oncology · Woodbury, NYNPI 1235180464
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $123,592 of the $149,128 with a category attached, or 82.9%. 14 manufacturers reported payments, led by AstraZeneca at 37.4% of the total. Reporting peaked in 2024 at $61,647 and has fallen 67.6% since, to $19,953 in 2025. Among hematology & oncology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 117 payments — averaging $1274.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$56K
- Sanofi$40K
- Novartis$26K
- Recordati_rare_diseases_inc.$10K
- Janssen Global Services, LLC$5K
- Janssen Scientific Affairs, LLC$3K
- plus $8K from 8 others
Across 360 payments — averaging $8604.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$2.3M
- Sanofi US Services Inc.$223K
- Bioverativ Therapeutics Inc.$205K
- Incyte Corporation$153K
- Sanofi$88K
- Janssen Research & Development, LLC$70K
- plus $77K from 3 others
What the payments were for
- Consulting fees$123,59283%
- Speaking & faculty fees$12,6208%
- Travel & lodging$9,8037%
- Food & beverage$3,0982%
- Education$160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 44 | $55,810 |
| Sanofi | 23 | $40,025 |
| Novartis | 15 | $26,265 |
| Recordati_rare_diseases_inc. | 7 | $9,817 |
| Janssen Global Services, LLC | 3 | $5,490 |
| Janssen Scientific Affairs, LLC | 2 | $3,417 |
| Janssen Research & Development, LLC | 14 | $3,302 |
| Rigel Pharmaceuticals, Inc. | 3 | $2,600 |
| Myovant Sciences Inc. | 1 | $2,240 |
| Incyte Corporation | 1 | $81 |
| Dendreon Pharmaceuticals LLC | 1 | $26 |
| AVEO Pharmaceuticals, Inc. | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$149,128 in reported general payments places this provider in the 95th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NinlaroIxazomib Citrate | 11 | $136,503 |
| EliquisApixaban | 94 | $73,786 |
| XareltoRivaroxaban | 46 | $27,975 |
| Enoxaparin Sodium | 11 | $2,518 |
| Hydroxyurea | 49 | $1,095 |
| ValacyclovirValacyclovir Hcl | 33 | $301 |
| Dexamethasone | 14 | $246 |
| Azathioprine | 14 | $160 |
| Pantoprazole Sodium | 19 | $74 |
| Allopurinol | 11 | $67 |
| Atorvastatin Calcium | 12 | $66 |
| Prednisone | 18 | $56 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Woodbury
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Francis ArenaLake Success$1M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
- Perry CookBrooklyn$803K
- Mihir RavalAlbany$767K
- Joshua SabariNew York$761K
- Gail RobozNew York$738K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.